# EDGAR Filing Document

**Accession Number:** 0002084869
**File Stem:** 0002084869-25-000001
**Filing Date:** 2025-9
**Character Count:** 5816
**Document Hash:** f15735da596733b21b069f5ded5999e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002084869-25-000001.hdr.sgml**: 20250925

**ACCESSION NUMBER**: 0002084869-25-000001

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250916

**FILED AS OF DATE**: 20250925

**DATE AS OF CHANGE**: 20250925

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** de la Huerta Martinez Maria del Pilar
- **CENTRAL INDEX KEY:** 0002084869

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40943
- **FILM NUMBER:** 251343203

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** HEMMELRATHER WEG 201
- **CITY:** LEVERKUSEN
- **PROVINCE COUNTRY:** 2M
- **ZIP:** D-51377
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Biofrontera Inc.
- **CENTRAL INDEX KEY:** 0001858685
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473765675
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801
- **BUSINESS PHONE:** 781-245-1325

**MAIL ADDRESS:**
- **STREET 1:** 120 PRESIDENTIAL WAY,
- **STREET 2:** SUITE 330
- **CITY:** WOBURN
- **STATE:** MA
- **ZIP:** 01801

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>de la Huerta Martinez Maria del Pilar<br><sub>(Last) (First) (Middle)</sub><br>HEMMELRATHER WEG 201<br><sub>(Street)</sub><br>LEVERKUSEN, 2M D-51377<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Biofrontera Inc. [ BFRI ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-09-16 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 400000 | I | By Biofrontera AG<sup>(1)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series D Convertible Preferred Stock | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 4831172 | $0.0006 | I | By Biofrontera AG<sup>(1)</sup> |

---

### Footnotes:

(1) The reported shares are held directly by Biofrontera AG.  The Reporting Person may be deemed to beneficially own the shares owned by Biofrontera AG because of her position as the sole member of the management board of Biofrontera AG.  The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of her indirect pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

(2) The convertible preferred stock is convertible at any time, at the holder's election, and has no expiration date.

**Remarks:**
Biofrontera AG has entered into an agreement with the Issuer pursuant to which Biofrontera AG may appoint one representative to the board of directors of the Issuer. Dr. Heikki Lanckriet has been deputized to represent Biofrontera AG on the board of directors of the Issuer. By virtue of Dr. Lanckriet's representation and the Reporting Person's position as the sole member of the management board of Biofrontera AG, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Dr. Lanckriet has filed a separate Section 16 report disclosing securities of the Issuer he may be deemed to beneficially own for Section 16 purposes.

**Signature:** /s/ Maria del Pilar de la Huerta Martinez  
**Date:** 2025-09-25

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**